Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS) - Hughes, Timothy P.; Hochhaus, Andreas; Branford, Susan; Müller, Martin C.; Kaeda, Jaspal S.; Foroni, Letizia; Druker, Brian J.; Guilhot, François; Larson, Richard A.; O'Brien, Stephen G.; Rudoltz, Marc S.; Mone, Manisha; et al. (Blood, 2010)
Keywords: Adolescent; Adult; Aged; Antineoplastic Agents - therapeutic use; Benzamides; Biological and medical sciences; Clinical Trials and Observations; Disease-Free Survival; Female; Genes, abl; Hematologic and hematopoietic diseases; Humans; Imatinib Mesylate; Interferons - therapeutic use; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical sciences; Middle Aged; Piperazines - therapeutic use; Prognosis; Pyrimidines - therapeutic use; Remission Induction; Time Factors; Treatment Outcome; Young Adult; Antineoplastic agent; Imatinib; Iris (eye); Prognosis; Hematology; Enzyme; Tyrosine kinase inhibitor; Transferases; Cytokine; Enzyme inhibitor; Chronic myelogenous leukemia; Early stage; Malignant hemopathy; Long term; Myeloproliferative syndrome; Randomization; Early; Interferon; Protein-tyrosine kinase; Cancer; International